NHS England has removed a statement saying 137 hospital trusts were benefiting from Palantir's federated data platform. The change followed Guardian reporting that 29 listed trusts were not using all or most of the system. The Guardian
Key facts
NHS England had listed 137 trusts as live on the federated data platform and benefiting from it. The Guardian
The system is intended to help organise information across hospital operations, including theatre use, patient pathways and discharge planning. The Guardian
Medact gathered information from hospitals and integrated care boards through freedom-of-information requests. The Guardian
NHS removes a disputed list of benefits
NHS England has taken down a detailed list claiming that 137 trusts were benefiting from Palantir's federated data platform after local responses challenged how widely it was being used. The Guardian reports that a less detailed page now describes reduced administration and faster pathways among early users.
The change matters because ministers are considering the supplier's future while hospitals, staff and patients need a clear account of what the platform is actually delivering.
A count of users became a disputed benefit claim
NHS England had listed 137 trusts as live on the federated data platform and benefiting from it. The Guardian found 29 trusts that said they were not using all or most of its applications. A deployment label, access to software and measurable improvements in care are different things. Treating them as interchangeable makes it difficult to judge whether a large public contract is delivering its intended results. Reporting context: The Guardian
The platform's proposed role
The system is intended to help organise information across hospital operations, including theatre use, patient pathways and discharge planning. Those are important administrative problems, but a claim of improvement needs a clear baseline and attribution. More operations or quicker discharges can have several causes. The Office for Statistics Regulation had already challenged evidence behind a separate claim about additional operations associated with the platform.
Freedom-of-information responses matter
Medact gathered information from hospitals and integrated care boards through freedom-of-information requests. That process tested central promotional statements against local accounts of actual use. Removal of the detailed list does not answer every question raised by those responses. It leaves a need for transparent definitions of adoption, active use and benefit, alongside a consistent explanation of how each is measured.
The contract decision remains separate
Ministers were considering an extension of Palantir's £330 million contract to 2029. Critics including health unions and campaign groups want an alternative approach, while Palantir argues that ending the relationship would put political objections ahead of patient needs. These competing positions concern procurement and policy; neither supplies an independent measurement of clinical or operational performance. Reporting context: The Guardian
Transition is part of the argument
Opponents point to contractual assistance provisions that they believe could support a move away from Palantir in 2027. Others favour continuity while replacement technology is developed. Any transition would involve more than changing a supplier's name: hospitals would need usable tools, support and clarity about data handling. The immediate issue is whether the public can assess those choices using reliable, comparable evidence. Reporting context: The Guardian
The alternative proposal and the lobbying around it
Labour MP Ben Coleman wants a UK-developed open platform on which trusts and British technology companies can build tools. That is a proposed direction for future procurement, rather than an existing replacement described as ready for immediate deployment.
The Guardian also reports that Palantir hired Labour peer Tom Watson as a full-time lobbyist. He wrote to the health secretary offering help with Britain's technological capability. Meanwhile, Unison, Doctors Association UK, Medact, Amnesty UK and patient group Just Treatment have pressed ministers to reject an extension. These interventions explain the intensity of the decision, but public arguments about sovereignty and political relationships still need to be assessed separately from evidence about the software's actual performance. NHS England did not respond to the Guardian's request for comment.
Questions readers ask
Does a trust being listed as live prove that the platform improved patient care?
No. Access, actual use and measurable outcomes are different questions. The Guardian reported that 29 of the listed trusts said they were not using all or most of the applications. The Guardian
Sources and editorial notes
This article compiles the linked reporting. Allegations, projections and research findings retain their original qualifications; this page does not represent independent field reporting or expert medical review.
- The Guardian (reporting)
November 17, 2026: Replaced repeated summary and FAQ templates, added source attribution and image description, and clarified the distinction between source publication and site edits. This editorial update is not an independent fact-check certification.



